Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
133 hedge funds and large institutions have $268M invested in Esperion Therapeutics in 2021 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 45 increasing their positions, 26 reducing their positions, and 49 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
96.54% more ownership
Funds ownership: 87.84% → 184.38% (+97%)
73% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 26
46% more call options, than puts
Call options by funds: $5.13M | Put options by funds: $3.51M
4% less funds holding
Funds holding: 139 → 133 (-6)
10% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 49
10% less capital invested
Capital invested by funds: $299M → $268M (-$31.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$40M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$24.9M |
| 3 |
ACM
Altium Capital Management
New York
|
+$20.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.4M |
| 5 |
MG
Meditor Group
Hamilton,
Bermuda
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$6.27M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$3.54M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$1.99M |
| 4 |
LA
Linden Advisors
New York
|
-$1.41M |
| 5 |
CCM
Cinctive Capital Management
New York
|
-$1.33M |
ESPR Hedge Fund Activity: Q4 2021 in Review
133 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2021, worth a combined $268M — down 10% from $299M a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of ESPR and 44 opened new positions — a net loss of 5 holders — while 26 trimmed existing stakes and 45 added.
The largest buyer was Deerfield Management, opening a new position worth an estimated $40M. The largest seller was Marshall Wace, exiting entirely with an estimated $6.27M sold.
- 133 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2021, down from 139 in Q3 2021.
- Funds reported $268M of Esperion Therapeutics stock for Q4 2021, down 10% quarter-over-quarter.
- 44 funds opened new Esperion Therapeutics positions in Q4 2021 and 49 closed out, a net change of -5 holders.
- The largest Esperion Therapeutics buyer in Q4 2021 was Deerfield Management, an estimated $40M added.
- The largest Esperion Therapeutics seller in Q4 2021 was Marshall Wace, an estimated $6.27M sold.
Based on aggregated 13F filings for Q4 2021.